WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Samir Elamrani
Partner Emeritus
Patents and Innovations
Download vCard
Open PDF
  • Former Patents and Innovations Department Leader

    With over 20 years of experience, Samir advised biotechnology, pharmaceutical, and nanotechnology clients on all aspects of patent law and related business matters.

  • Strategic IP Counseling Expertise

    Samir provided outside patent counsel to a variety of clients, including start-up and established Life Science corporations.

  • Informed Technical Expertise

    Samir earned a Ph.D. in chemistry and conducted research at top American and European academic institutions prior to starting his patent law career.

Dr. Samir Elamrani retired as a partner in the patents and innovations department at Wilson Sonsini Goodrich & Rosati in 2025. He was a partner in the firm's San Diego office, where he advised biotechnology, pharmaceutical, and nanotechnology clients on all aspects of patent law and related business matters.

With his substantial expertise in strategic IP counseling and global patent portfolio development and management, he provided outside patent counsel to a variety of clients, including start-up and established biotechnology corporations, multinational pharmaceutical corporations, and premier research universities. He has prepared numerous due diligence reports and counseled clients in matters relating to the transfer of intellectual property, including acquisition and licensing of patent rights.

Prior to joining the firm, Samir was counsel at Crowell & Moring and a senior associate at Pillsbury Winthrop LLP, where he counseled clients in the biotechnology, pharmaceutical, and chemical industries. While attending law school, Samir was a full-time patent law clerk and patent agent at Burns Doane Swecker & Mathis, a large intellectual property firm, where he counseled clients in matters before the United States Patent and Trademark Office (USPTO). Samir has prepared and prosecuted over 250 U.S., Patent Cooperation Treaty, and foreign applications, covering inventions relating to small molecule pharmaceuticals, molecular design, structural biology, therapeutic peptides, proteins, vaccines, genes, gene therapy, anti-sense technology, recombinant antibodies, fuel-cell technology, zeolites, and noble metal catalysts.

Before starting a career in patent law, Samir conducted extensive research in premier American and European academic institutions. His experience relates to the areas of computational structural biology, protein dynamics, drug design, host-guest modeling, heterogeneous catalysis, and zeolite chemistry. During his academic tenure, Samir published a Ph.D. dissertation on global motions in proteins and a French doctorate dissertation on molecular diffusion inside zeolite pores.

Samir is fluent in English, French, and Arabic.

Experience

Dr. Samir Elamrani retired as a partner in the patents and innovations department at Wilson Sonsini Goodrich & Rosati in 2025. He was a partner in the firm's San Diego office, where he advised biotechnology, pharmaceutical, and nanotechnology clients on all aspects of patent law and related business matters.

With his substantial expertise in strategic IP counseling and global patent portfolio development and management, he provided outside patent counsel to a variety of clients, including start-up and established biotechnology corporations, multinational pharmaceutical corporations, and premier research universities. He has prepared numerous due diligence reports and counseled clients in matters relating to the transfer of intellectual property, including acquisition and licensing of patent rights.

Prior to joining the firm, Samir was counsel at Crowell & Moring and a senior associate at Pillsbury Winthrop LLP, where he counseled clients in the biotechnology, pharmaceutical, and chemical industries. While attending law school, Samir was a full-time patent law clerk and patent agent at Burns Doane Swecker & Mathis, a large intellectual property firm, where he counseled clients in matters before the United States Patent and Trademark Office (USPTO). Samir has prepared and prosecuted over 250 U.S., Patent Cooperation Treaty, and foreign applications, covering inventions relating to small molecule pharmaceuticals, molecular design, structural biology, therapeutic peptides, proteins, vaccines, genes, gene therapy, anti-sense technology, recombinant antibodies, fuel-cell technology, zeolites, and noble metal catalysts.

Before starting a career in patent law, Samir conducted extensive research in premier American and European academic institutions. His experience relates to the areas of computational structural biology, protein dynamics, drug design, host-guest modeling, heterogeneous catalysis, and zeolite chemistry. During his academic tenure, Samir published a Ph.D. dissertation on global motions in proteins and a French doctorate dissertation on molecular diffusion inside zeolite pores.

Samir is fluent in English, French, and Arabic.

Education
  • J.D., University of Houston Law Center, 1999
  • Ph.D., Chemistry (Computational Molecular Structural Biology), Institute of Molecular Design, University of Houston, 1996
  • Ph.D., Chemistry (Catalysis), Université Claude Bernard, 1990
  • M.S., Theoretical and Computational Chemistry, Université Paris XI, 1987
  • B.S., Chemistry, Université Mohammed V Rabat, 1986
Credentials
Education
  • J.D., University of Houston Law Center, 1999
  • Ph.D., Chemistry (Computational Molecular Structural Biology), Institute of Molecular Design, University of Houston, 1996
  • Ph.D., Chemistry (Catalysis), Université Claude Bernard, 1990
  • M.S., Theoretical and Computational Chemistry, Université Paris XI, 1987
  • B.S., Chemistry, Université Mohammed V Rabat, 1986

Select Publications

  • Co-author with M. B. Berry, G. N. Phillips, Jr., and J. A McCammon, "Study of global motions in proteins by weighted masses molecular dynamics: adenylate kinase as a test case," Proteins 25, 79-88, 1996
  • Co-author with B. A. Luty and J. A. McCammon, "Simulation of the bimolecular reaction between superoxide and superoxide dismutase: synthesis of the encounter and reaction steps," Journal of the American Chemical Society, 1993
  • Co-author with M. Kolb, "Molecular dynamics simulations in zeolites: from deterministic to random motion," Journal of Chemical Physics 98(2), 1993
  • Co-author with F. Vigne-Maeder and B. Bigot, "Self-diffusion of rare gases in silicalites studied by molecular dynamics," Journal of Physical Chemistry 96 (9417-21), 1992
  • Co-authors with F. Vigne-Maeder and P. Gelin, "An approach to the surface barrier problem in diffusion in zeolites by computer simulation," Journal of Catalysis 134 (536-41), 1992
Insights

Select Publications

  • Co-author with M. B. Berry, G. N. Phillips, Jr., and J. A McCammon, "Study of global motions in proteins by weighted masses molecular dynamics: adenylate kinase as a test case," Proteins 25, 79-88, 1996
  • Co-author with B. A. Luty and J. A. McCammon, "Simulation of the bimolecular reaction between superoxide and superoxide dismutase: synthesis of the encounter and reaction steps," Journal of the American Chemical Society, 1993
  • Co-author with M. Kolb, "Molecular dynamics simulations in zeolites: from deterministic to random motion," Journal of Chemical Physics 98(2), 1993
  • Co-author with F. Vigne-Maeder and B. Bigot, "Self-diffusion of rare gases in silicalites studied by molecular dynamics," Journal of Physical Chemistry 96 (9417-21), 1992
  • Co-authors with F. Vigne-Maeder and P. Gelin, "An approach to the surface barrier problem in diffusion in zeolites by computer simulation," Journal of Catalysis 134 (536-41), 1992
Focus Areas
  • Biotech
  • Global Generics
  • Intellectual Property
  • Life Sciences
  • Medical Devices
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises LinusBio on $16 Million Financing to Help Diagnose Autism
On January 6, 2023, Linus Biotechnology received $16 million in venture capital financing for its R&D efforts to establish a method for predicting a child's chances of developing autism using information gleaned from a single piece of hair. Launched in late 2021, the spinout from Mount Sinai Health System said it hopes the funding will help grow its team and enable it to deliver “tangible outcomes” and the clinical data necessary to demonstrate its test can act as an accurate diagnostic aid for autism—even as early as just after birth. LinusBio’s $16 million Series A round was led by GreatPoint Ventures and Bow Capital and joined by Divergent Investments, Bia-Echo Foundation President Nicole Shanahan, the David Bellet Family Office, Gillian Sandler, and Francisco Partners co-founder Sanford Robertson, among others. Wilson Sonsini Goodrich & Rosati represented LinusBio in the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Azurity on Acquisition, Merger with Arbor Pharmaceuticals
On August 24, 2021, Azurity Pharmaceuticals, Inc. and Arbor Pharmaceuticals, Inc. announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions. Financial details of the transaction were not disclosed.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.